samedan logo
 
 
spacer
home > pmps > winter 2021 > pandemic poses cold chain challenges
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Pandemic Poses Cold Chain Challenges

As the world watched, the first approved COVID-19 vaccines were transported to the UK to start the mass immunisation process.

The global attention not only highlighted how the pharmaceutical manufacturing and supply chain sectors were working together to rapidly respond in the fight against the virus, it also focused on the cold chain challenges associated with the deployment and safe transportation of COVID-19 vaccines.

These challenges will continue to evolve as various vaccines, with varying temperature requirements for storage and shipment, are approved and transported worldwide.

Cold chain protection, throughout this distribution process, is essential. This can be packaging, or buildings and vehicles, but most crucial is a process to establish an unbroken cold chain. Colder temperatures are more difficult to maintain, as they may require more exotic coolants, such as dry ice, to achieve -80°C.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adam Tetz is the Director of Worldwide Marketing at Peli BioThermal, and has more than 25 years of marketing experience. He is responsible for telling the story of Peli BioThermal to our worldwide audiences. His areas of responsibility include brand identity, product launch, and communication strategy. Prior to Peli BioThermal, Adam held positions in product management and marketing communication across a variety of industries, including medical software, financial software, information services, and professional consulting services. He holds an MBA in Marketing from the University of Saint Thomas, US, a BA in Advertising from the University of Minnesota, US, and is a veteran of the United States Coast Guard.
spacer
Adam Tetz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta").
More info >>

White Papers

Pandemic respiratory vaccine clinical trials: a departure from business as usual

ICON plc

Around the world, the “V” words are on everyone’s lips: Virus and Vaccines. In response to the urgent need for a vaccine for COVID-19, researchers are, at time of publication, running 500+ clinical trials (and counting) on a number of antivirals, antibodies and vaccines. Promising possibilities range from novel new drugs/vaccines, repurposing treatments currently indicated for HIV, Ebola and malaria, to monoclonal antibodies and immune serum.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement